Osumi-Sutherland, David
Xu, Chuan
Keays, Maria
Levine, Adam P.
Kharchenko, Peter V. http://orcid.org/0000-0002-6036-5875
Regev, Aviv
Lein, Ed
Teichmann, Sarah A. http://orcid.org/0000-0002-6294-6366
Article History
Received: 18 May 2021
Accepted: 28 September 2021
First Online: 8 November 2021
Competing interests
: Since January 2019, S.A.T. has been remunerated for consulting and SAB membership by Foresite Labs, GlaxoSmithKline, Biogen, Roche and Genentech, and is a founder and equity holder of Transition Bio. A.R. is a cofounder and equity holder in Celsius Therapeutics, an equity holder in Immunitas Therapeutics, and was a scientific advisory board member for ThermoFisher Scientific, Asimov, Syros Pharmaceuticals and Neogene Therapeutics until 31 July 2020. From 1 August 2020, A.R. is an employee of Genentech, a member of the Roche group. A.R. is a named inventor on several patents and patent applications filed by the Broad Institute in the area of single-cell and spatial genomics. The other authors declare no competing interests.
Free to read: This content has been made available to all.